Unveiling Key Insights on Haleon – A Stock Analysis

By Scott Lee • Monday, March 18 15:11 • Permanent Link

Large-cap Consumer Discretionary company Haleon has moved -3.2% so far today on a volume of 9,053,395, compared to its average of 4,046,051. In contrast, the S&P 500 index moved 1.0%.

Haleon trades -17.06% away from its average analyst target price of $9.7 per share. The 2 analysts following the stock have set target prices ranging from $9.35 to $10.05, and on average have given Haleon a rating of buy.

Anyone interested in buying HLN should be aware of the facts below:

Haleon has moved 4.8% over the last year, and the S&P 500 logged a change of 29.5%
Based on its trailing earnings per share of 0.29, Haleon has a trailing 12 month Price to Earnings (P/E) ratio of 27.7 while the S&P 500 average is 15.97
HLN has a forward P/E ratio of 19.2 based on its forward 12 month price to earnings (EPS) of $0.42 per share
Its Price to Book (P/B) ratio is 4.47 compared to its sector average of 4.24
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific.
Based in Weybridge, the company has 25,408 full time employees and a market cap of $37.18 Billion. Haleon currently returns an annual dividend yield of 0.7%.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.